Healthcare provider profile · identity verified

Michael W Lin, MD

Endocrinology · SAN GABRIEL, CA · NPI 1285661819

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	1478	364
Metformin Hcl	Metformin Hcl	1123	246
Glimepiride	Glimepiride	1074	216
Jardiance	Empagliflozin	1011	168
Metformin Hcl Er	Metformin Hcl	935	205
Methimazole	Methimazole	698	163
Pioglitazone Hcl	Pioglitazone Hcl	520	104
Repaglinide	Repaglinide	503	106
Farxiga	Dapagliflozin Propanediol	413	82
Rybelsus	Semaglutide	402	79
Januvia	Sitagliptin Phosphate	397	75
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	354	73
Humalog Mix 50-50 Kwikpen	Insulin Lispro Protamin/Lispro	320	59
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	312	110
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	306	74
Glipizide Er	Glipizide	301	59
Ozempic	Semaglutide	298	66
Nateglinide	Nateglinide	288	53
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	232	43
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	216	63
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	210	65
Tradjenta	Linagliptin	209	45
Humalog Kwikpen U-100	Insulin Lispro	196	61
Janumet	Sitagliptin Phos/Metformin Hcl	164	31
Acarbose	Acarbose	156	37
Novolog Flexpen	Insulin Aspart	145	52
Alcohol Prep Pads	Alcohol Antiseptic Pads	143	36
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	133	37
Comfort Ez Pen Needle	Pen Needle, Diabetic	131	41
Glipizide	Glipizide	128	30
Trulicity	Dulaglutide	126	24
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	123	33
Janumet Xr	Sitagliptin Phos/Metformin Hcl	118	22
Tresiba Flextouch U-100	Insulin Degludec	102	32
Calcitriol	Calcitriol	101	28
Tresiba Flextouch U-200	Insulin Degludec	98	18
Fiasp Flextouch	Insulin Aspart (Niacinamide)	92	21
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	88	21
Synthroid	Levothyroxine Sodium	87	27
Lantus	Insulin Glargine,hum.Rec.Anlog	78	19
Novolin R Flexpen	Insulin Regular, Human	77	16
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	75	16
Atorvastatin Calcium	Atorvastatin Calcium	74	26
Losartan Potassium	Losartan Potassium	68	17
Hydrocortisone	Hydrocortisone	67	16
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	62	suppressed
Insulin Aspart Flexpen	Insulin Aspart	62	17
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	62	16
Propylthiouracil	Propylthiouracil	61	14
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	60	11
Alendronate Sodium	Alendronate Sodium	58	16
Mounjaro	Tirzepatide	55	11
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	55	12
Novolin N Flexpen	Insulin Nph Human Isophane	52	13
Raloxifene Hcl	Raloxifene Hcl	51	13
Invokana	Canagliflozin	50	11
Novolin R	Insulin Regular, Human	50	13
Dapagliflozin	Dapagliflozin Propanediol	49	26
Prednisone	Prednisone	49	11
Ulticare Pen Needle	Pen Needle, Diabetic	49	21
Admelog Solostar	Insulin Lispro	46	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	45	13
Cinacalcet Hcl	Cinacalcet Hcl	43	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	42	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	37	suppressed
Humalog	Insulin Lispro	37	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	37	14
Teriparatide	Teriparatide	36	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	35	20
Synjardy	Empagliflozin/Metformin Hcl	35	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Humulin R	Insulin Regular, Human	32	suppressed
Testosterone	Testosterone	32	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	31	13
Metoprolol Succinate	Metoprolol Succinate	31	suppressed
Simvastatin	Simvastatin	31	suppressed
Testosterone Cypionate	Testosterone Cypionate	30	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	28	12
Cabergoline	Cabergoline	27	suppressed
Liothyronine Sodium	Liothyronine Sodium	23	suppressed
Prolia	Denosumab	23	13
Sure Comfort Pen Needle	Pen Needle, Diabetic	23	14
Novolog	Insulin Aspart	22	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	21	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	20	suppressed
Novofine 32	Pen Needle, Diabetic	20	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	20	suppressed
Spironolactone	Spironolactone	18	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	18	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	18	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Humalog Kwikpen U-200	Insulin Lispro	16	suppressed
Insulin Aspart Prot Mix 70-30	Insulin Aspart Prot/Insuln Asp	16	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Insulin Lispro	Insulin Lispro	15	suppressed
Novolin N	Insulin Nph Human Isophane	15	suppressed
Armour Thyroid	Thyroid,pork	14	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	14	suppressed
Techlite Pen Needle	Pen Needle, Diabetic	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	13	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	13	suppressed
Demeclocycline Hcl	Demeclocycline Hcl	12	suppressed
Desmopressin Acetate	Desmopressin (Nonrefrigerated)	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Easy Touch	Syringe-Needle,insulin,0.5 Ml	12	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	12	suppressed
Fiasp	Insulin Aspart (Niacinamide)	12	suppressed
Glucagon Emergency Kit	Glucagon	12	suppressed
Levemir	Insulin Detemir	12	suppressed
Monoject Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Steglatro	Ertugliflozin Pidolate	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Admelog	Insulin Lispro	11	suppressed
Amlodipine Besylate	Amlodipine Besylate	11	suppressed
Lisinopril	Lisinopril	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Novolog Mix 70-30	Insulin Aspart Prot/Insuln Asp	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error